Business Wire

SHISEIDO/MA-CBRC

Share
Shiseido Marks the 30th Anniversary of Joint Research in Dermatology

Shiseido Company, Limited (“Shiseido”) has agreed on Tuesday, September 17, 2019 to extend for a further six years its research alliance with the dermatological laboratory CBRC (Cutaneous Biology Research Center), established by Harvard Medical School Dermatology Research Labs, and Massachusetts General Hospital in Boston, Massachusetts, USA. This new agreement will be effective July 2021 through June 2027.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190917006201/en/

The CBRC was founded in 1989, and is known as a world-class laboratory in the field of dermatology. Shiseido has been collaborating for 30 years with the CBRC as a pioneer of open innovation pursuing unprecedented research collaboration with external organizations both nationally and internationally. Many of the cutting-edge research results are utilized in our product research and development.

Going forward, to achieve our corporate mission, “BEAUTY INNOVATIONS FOR A BETTER WORLD,” Shiseido will continue joint research with the CBRC and create cutting-edge value through research in dermatology including ultraviolet rays and aging, as well as development of innovative cosmetic products. Furthermore, in addition to research and development, we will also provide consumers with information to maintain healthy skin, such as basic knowledge on UV rays and the impact of photoaging, etc. through seminars and symposiums.

To celebrate the 30th anniversary of the CBRC and new six-year extension of the alliance, three representatives—Shiseido’s President and CEO Masahiko Uotani, Executive Vice President Yoichi Shimatani, and CBRC Director David E. Fisher, MD, PhD—gave comments as follows:

Shiseido’s President and CEO, Masahiko Uotani:
“In our quest to remain vital for the next 100 years and beyond, this year, we at Shiseido created a new corporate mission “BEAUTY INNOVATIONS FOR A BETTER WORLD.” Ongoing efforts to foster innovation is our responsibility and mission to make this world better through the power of beauty. The CBRC is an indispensable and important partner for Shiseido to create unprecedented, first-of-its-kind value and change the lives of people around the world. Let us cling together for the future and challenge for the innovation that surpasses society's expectations.”

Executive Vice President, Yoichi Shimatani:
“It has been 30 years since we began our partnership with the CBRC. We have delivered many outstanding research achievements, more than we had initially imagined, realizing ideal collaboration between laboratories in academia and a company. We will continue to create innovation with the CBRC, a state-of-the-art laboratory that symbolizes our open innovation activities.”

CBRC Director, David E. Fisher:
“The Shiseido-CBRC relationship is a source of immense pride to Dermatology at Mass General Hospital/Harvard Medical School. Close collaboration at the cutting edge of science is the shared mission, and numerous significant discoveries continue to be made through common efforts. We are proud to celebrate 30 years of important discoveries by our scientists working together, and look forward to continued progress in optimizing all aspects of skin health and wellbeing.”

About CBRC
The CBRC is a general research institute for advanced research and development in the field of dermatology established by Harvard Medical School and Massachusetts General Hospital with support from Shiseido in 1989. We started collaborative research 30 years ago and since then we have achieved many remarkable research results in skin and hair science. Many researchers have also been dispatched from Shiseido, contributing to the cultivation of global research talent.

[Reference]
Major joint research achievements between the CBRC and Shiseido in the past 30 years

The world’s first research achievements in skin and hair science.

Year

Achievements

1993

"Regulation of Langerhans cell function by nerves containing calcitonin gene-related peptide"

Through this discovery, provided a lead to elucidate the phenomenon that skin diseases observed in clinical settings are exacerbated by mental stress. This research paper was published in science journal Nature in 1993, and many related research papers were presented.

2001

"Importance of balance between extracellular matrix synthesis and degradation in basement membrane formation"

Clarified the importance of the balance in biosynthesis and degradation of laminin 5 and type VII collagen in basement membrane formation, and the mechanism that promotes the formation. Shiseido won the IFSCC* top award in 2000 for related research.

2003

"Profile of transforming growth factor-beta responses during the murine hair cycle"

Discovered the mechanism of two genes TSC-22 and Smad2 involved in epilation.

2005

"Ultraviolet B-induced skin angiogenesis is associated with a switch in the balance of vascular endothelial growth factor and thrombospondin-1 expression"

Elucidated that the induction of capillaries beneath the epidermis due to UV irradiation causes wrinkles.

2007

"Dedicated epithelial recipient cells determine pigmentation patterns"

Newly found that pigment recipient cells send a signal to pigment cells to determine the pigmentation pattern. This research paper was published in the world-renowned academic journal Cell in 2007.

2009

"Hepatocyte growth factor promotes lymphatic vessel formation and function"

"A Novel Mechanism of Cutaneous Photo-Aging Mediated by the Impairment of Lymphatic Function and the Protective Role of a Lymphatic-promoting Compound”

Discovered that UV-exposed skin deteriorates the function of lymphatic vessels, leading to the creation of wrinkles. Furthermore, developed the drug that suppresses the phenomenon.

2010

“Reduction of oxidative stress in living body by promoting expression of redox-related factors”

Discovered that kaempferol, a kind of polyphenol, and ginkgo biloba, which contains kaempferol, significantly suppress the level of cell damage caused by UV rays. Shiseido and CBRC jointly own the patents (joint applications).

2016

"Ex-vivo demonstration of the disruption of skin homeostasis and the role of extracellular ATP in the reaction"

"Ex-vivo analysis of localized response to environmental stress in human skin"

Discovered that heparanase, one of the factors that promote basement membrane degradation, increases in the epidermis due to external environmental stress such as dryness.

* IFSCC (The International Federation of Societies of Cosmetic Chemists): An international organization dedicated to the development of highly functional and safe cosmetic technology through the world-wide cooperation of cosmetic societies.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis2.6.2025 13:00:00 CEST | Press release

ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis. The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG. “This IND approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders”, said Dr. Dongjo Kim, the CEO of ImmunAbs, “we believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.” About Myasthenia Gravis

Lenovo and Bellevue University Team Up to Offer Supply Chain and Logistics Education to Deliver “Smarter Technology for All”2.6.2025 13:00:00 CEST | Press release

Learners will have access to Lenovo’s globally recognized supply chain expertise through real-world case studies and subject matter experts. Lenovo, the global technology powerhouse, recognized in the top 10 in the Gartner Supply Chain Top 25, and Bellevue University, one of the nation’s top online universities, are teaming up to develop the next generation of supply chain professionals. “We believe that bringing real-world Global Supply Chain experience and learning directly into an education curriculum is precisely the optimal way to upskill the workforce of the future,” said Ben Massie, Vice President, Global Supply Chain, Lenovo. “Teaming up with Bellevue allows us to attract the right talent using the right technology and deliver on our mission to make ‘smarter technology for all’ a reality.” As a preferred higher education institution tapped to team up with Lenovo to offer supply chain short-term learning, Bellevue will leverage the breadth and depth of Lenovo’s supply chain expe

Lifezone Metals Files Initial Assessment for the Kabanga Nickel Project in Tanzania2.6.2025 12:30:00 CEST | Press release

Vertically Integrated Plan includes Hydrometallurgical Refinery at Kahama $2.37 Billion After-Tax NPV (8%) and 22.9% After-Tax IRR at $8.49 per Pound Nickel Price Initial Assessment Proposes a 22-Year Mine Plan at Average 2.39% Nickel Equivalent Grade Webcast with Technical Leadership Team at 10 AM ET on Tuesday, June 3, 2025 Lifezone Metals Limited’s (NYSE: LZM) Chief Executive Officer, Chris Showalter, and Chief Operating Officer, Gerick Mouton, announce today the results from the Initial Assessment for its flagship Kabanga Nickel Project in northwest Tanzania. The Initial Assessment evaluates a vertically integrated mining, processing and refining operation, commencing with a high-grade nickel sulfide underground mine and concentrator at the Kabanga site, followed five years later by a hydrometallurgical refinery at Kahama. The study covers the Main, MNB, Kima, North, and Tembo zones and is based on the December 2024 Mineral Resource Update (refer to Lifezone’s December 5, 2024 news

Corpay Cross-Border Named an Official Partner of Real Madrid C.F.2.6.2025 12:00:00 CEST | Press release

Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Real Madrid C.F. to become an Official Partner. Through this partnership, Real Madrid will be able to gain access to and utilise Corpay Cross Border’s innovative solutions to help mitigate foreign exchange exposure from their day-to-day business needs. "The Corpay Cross-Border team is elated to be named an Official Partner of Real Madrid, one of the world’s most widely recognized and followed sports franchises," said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “With our strong focus on growing the Corpay brand, as well as our currency risk management business, we are excited to partner with one of the most successful football clubs in the world.” About Corpay Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments co

BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 20252.6.2025 12:00:00 CEST | Press release

Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitorData underscore strength of emerging breast cancer pipeline as part of BeOne’s global transformation with next wave of innovation BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, including breast cancer, and BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), in HR+/HER2- breast cancer patients with prior CDK4/6i exposure. “Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,” said Mark Lanas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye